Zanganeh Mahkam reported option exercise involving 500,000 shares of Summit Therapeutics Inc. at $1.06 for $530k on Nov 16, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Co-Chief Executive Officer
Co-Chief Executive Officer
Filed Nov 16, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$530,000Shares × reported price
Shares traded
500,000Common Stock
Price per share
$1.06Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
531,000Direct
Trade date
Nov 16, 2026Option exercise
Filed
Nov 16, 2026, 8:23 PM ET1-day reporting delay
Accession
0001507650-26-000009Code M · Transaction 402305
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 16, 2026Option exercise500,000$0.00$0Trade 402306
2 transaction rows in this filing. Joint filers share the same rows.

SMMT price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SMMT · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −2.9%1w ago +18%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: On November 16, 2026, the Reporting Person exercised an option to purchase 500,000 shares of the Issuer's common stock at an exercise price of $1.06 per share. F2: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. F3: The option was granted on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025.